Episode 181 - May 1, 2026

The biotech sector maintains positive year-to-date performance, with the XBI index outperforming broader markets despite recent volatility. The IPO window remains open for high-quality, long-incubated companies, evidenced by ten successful debuts raising $3.2 billion. M&A activity continues to accelerate, driven by Eli Lilly’s aggressive acquisition strategy, which includes a $3.2 billion deal for Ajax Therapeutics. Pancreatic cancer has emerged as a critical focus area, highlighted by Revolution Medicines’ compelling phase three survival data, which contrasts with the mixed clinical results and patent litigation surrounding Eraska. While generalist investor interest remains elusive for earlier-stage assets, the industry is seeing a steady flow of capital into de-risked, commercial-stage opportunities. Patent settlements, such as those involving Pfizer’s tafamidis, further underscore the sector's evolving landscape as companies navigate patent cliffs and seek sustainable long-term growth.